Personalized Blood Clot Prevention After Surgery for Peripheral Artery Disease

What this Trial Is About

Researchers are evaluating a personalized blood clot prevention plan compared to standard treatment in adults with peripheral artery disease PAD who have had procedures to restore blood flow to their legs. The study aims to find out if the personalized plan can lower blood clots, amputations, repeat procedures, bleeding, and death rates over one year. The study focuses on improving care by tailoring medication based on individual blood test results rather than using a uniform approach. Participants are randomly assigned to either the TARGET personalized plan or standard care after their procedure. The TARGET plan uses a blood test called Thromboelastography with Platelet Mapping TEG-PM to monitor platelet inhibition and adjust antiplatelet medications accordingly. Blood tests occur at 1 week and 1, 3, 6, 9, and 12 months after surgery, with medication changes made if platelet inhibition falls outside a specific therapeutic range. The standard treatment group receives usual care without medication changes based on these tests. During the 12-month study, participants have multiple blood tests and clinical monitoring to assess blood clotting and bleeding events. Researchers measure the occurrence of arterial thrombosis in the treated leg as the main outcome after one year. Secondary outcomes include amputation-free survival, death from any cause, repeat procedures, and bleeding events. The study involves ongoing medication adjustments, safety monitoring, and data collection to understand if the personalized approach offers benefits over standard treatment.

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease